Related Experiment Videos
Myeloperoxidase -463 (G-->A) polymorphism associated with lower risk of lung cancer
Orhun H Kantarci1, Timothy G Lesnick, Ping Yang
1Department of Neurology, Mayo Clinic, Rochester, Minn 55905, USA.
Objective:
To study the association of the myeloperoxidase (MPO) -463 (G-->A) polymorphism with lung cancer risk.
Patients And Methods:
We performed a paired case-control analysis of 307 patients with primary lung cancer and an equal number of age-, sex-, and ethnicity-matched controls to evaluate the effect of the MPO -463 (G-->4A) polymorphism on disease susceptibility. We also performed conditional logistic regression analyses to evaluate the effect of the polymorphism adjusted for smoking status and chronic obstructive pulmonary disease, 2 established risk factors. We used 2 models for these analyses: one to compare homozygous (AA) genotypes with wild type (GG) and heterozygous (GA) genotypes and one to compare carriers (heterozygotes and AA homozygotes) with GG genotypes. Finally, we combined the results from the published studies of this putative association and performed a stratified analysis.
Results:
The AA genotype was inversely associated with susceptibility to lung cancer (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.15-1.00). There was no association in heterozygotes. However, in the stratified analysis, we found an association between patients with the AA (OR, 0.44; 95% CI, 0.27-0.68) and GA (OR, 0.77; 95% CI, 0.64-0.93) genotypes vs the GG genotype.
Conclusion:
Our results are consistent with previous reports and show that homozygotes of the less common A allele of MPO -463 polymorphism have a 2.6-fold lower risk of lung cancer.
Insights
The myeloperoxidase (MPO) -463 (G-->A) polymorphism, specifically the AA genotype, is associated with a significantly lower risk of developing lung cancer. This finding supports a protective role for this genetic variant against lung cancer development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- Lung cancer remains a leading cause of cancer-related mortality worldwide.
- Genetic predisposition plays a crucial role in lung cancer susceptibility.
- The myeloperoxidase (MPO) gene is implicated in inflammatory processes and oxidative stress, relevant to carcinogenesis.
Purpose of the Study:
- To investigate the association between the myeloperoxidase (MPO) -463 (G-->A) gene polymorphism and the risk of developing primary lung cancer.
- To evaluate the impact of MPO -463 genotypes on lung cancer susceptibility, considering established risk factors.
Main Methods:
- A paired case-control study involving 307 lung cancer patients and 307 matched controls.
- Conditional logistic regression analysis was employed to adjust for smoking status and COPD.
- Meta-analysis of published studies was conducted for stratified analysis.
Main Results:
- The AA genotype of the MPO -463 polymorphism showed an inverse association with lung cancer susceptibility (OR, 0.39; 95% CI, 0.15-1.00).
- No significant association was observed for the heterozygous GA genotype in initial analysis.
- Stratified analysis revealed an association for both AA (OR, 0.44) and GA (OR, 0.77) genotypes compared to GG.
Conclusions:
- Homozygotes for the less common A allele of the MPO -463 polymorphism exhibit a reduced risk of lung cancer.
- The findings are consistent with previous research, suggesting a protective effect of the MPO -463 A allele against lung cancer.
- This genetic polymorphism may serve as a potential biomarker for lung cancer risk assessment.